

Please type a plus sign (+) inside this box →





PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

 TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/531,547
	Filing Date	November 16, 2005
	First Named Inventor	KHOSLA, CHAITAN
	Group Art Unit	Unknown
	Examiner Name	Unknown
Total Number of Pages in This Submission	Attorney Docket Number STAN-258US5	
ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input checked="" type="checkbox"/> USPTO Form SB08A <input checked="" type="checkbox"/> 14 cited references <input type="checkbox"/> Certified Copy of Priority Documents <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Return postcard
Remarks		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Signing Attorney/Agent (Reg. No.)	PAMELA J. SHERWOOD, 36,677 BOZICEVIC, FIELD & FRANCIS, LLP	
Signature		
Date	June 30, 2006	

EXPRESS MAIL LABEL NO. EV 687 637 744 US

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Express Mail No. EV 687 637 744 US

INFORMATION
DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97

Address to:
Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Attorney Docket	STAN-258US5
First Named Inventor	KHOSLA, CHAITAN
Application Number	10/531,547
Confirmation No.	3888
International Filing Date	November 20, 2003
Group Art Unit	Unknown
Examiner Name	Unknown

Title: "DIAGNOSTIC METHOD FOR CELIAC SPRUE"

Sir:

Applicants hereby submit an Information Disclosure Statement along with attached form(s) PTO/SB/08. Copies of most of the listed publications are being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. Applicants further request that the Examiner initial and return the attached form(s) PTO/SB/08 in accordance with MPEP §609.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, prior art or material to patentability as defined in §1.56.

☒ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because:

- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage
-- OR --
- ☒ (3) It is being filed before the mail date of the first Office Action on the merits
-- OR --

☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

☒ Copies of references listed on the attached Form PTO/SB/08 are enclosed herewith EXCEPT THAT:


☒ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2). (The U.S. patents and each U.S. patent application publication listed on the attached Form PTO-1449 are not enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i)).

☒ One of the listed references is not in the English language; however, it is accompanied by an English-language abstract.

The Commissioner is hereby authorized to charge any underpayment of fees associated with this communication, including any necessary fees for extensions of time, or credit any overpayment to Deposit Account No. 50-0815, order number STAN-258US5.


Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: June 30, 2006

By: 
Pamela J. Sherwood
Registration No. 36,677

Bozicevic, Field & Francis, LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number		10/531,547		
		I.A. Filing Date		11-20-03		
		First Named Inventor		KHOSLA et al.		
		Art Unit				
		Examiner Name				
Sheet	1	of	2	Attorney Docket Number		STAN-258US5

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
		US- 2001/0036639		11-01-01	FINE	
		US- 2003/0215438		11-20-03	HAUSCH	
		US- 5,834,428		11-10-98	DRUCKER	
		US- 6,319,726		11-20-01	SCHUPPAN	
		US- 6,410,550		06-25-02	COE	

FOREIGN PATENT DOCUMENTS						
Examiner Initials'	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
		EP 0 905 518 A1	03-31-1999	KONING		
		WO 94/26774	11-24-1994	ALEXANDER		
		WO 01/25793 A2	04-12-2001	ANDERSON		
		WO 03/068170	08-21-2003	HAUSCH		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		AHNEN et al., INTESTINAL AMINOOLIGOPEPTIDASE. IN VIVO SYNTHESIS ON INTRACELLULAR MEMBRANES OF RAT JEJUNUM, 1982, J. Biol. Chem., 257, 12129-35	
		ARENTZ-HANSEN et al., THE INTESTINAL T CELL RESPONSE TO α - GLIADIN IN ADULT CELIAC DISEASE IS FOCUSED ON A SINGLE DEAMIDATED GLUTAMINE TARGETED BY TISSUE TRANSGLUTAMINASE, 2000, J. Exp. Med., 191, 603-12	
		BORDUSA et al., THE SPECIFICITY OF PROLYL ENDOPEPTIDASE FROM FLAVOBACTERIUM MENINGOSEPTUM: MAPPING THE S' SUBSITES BY POSITIONAL SCANNING VIA ACYL TRANSFER, 1998, Bioorg. Med. Chem., 6, 1775-80	
		COLOT et al., THE GENES ENCODING WHEAT STORAGE PROTEINS: TOWARDS A MOLECULAR UNDERSTANDING OF BREAD-MAKING QUALITY AND ITS GENETIC MANIPULATION, 1990, Genet Eng., 12:225-41	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/531,547		
		I.A. Filing Date	11-20-03		
		First Named Inventor	KHOSLA et al.		
		Art Unit			
Examiner Name					
Sheet	2	of	2	Attorney Docket Number	STAN-258US5

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Database DERWENT, ACC-NO 1996-329479, HLA-BINDING OLIGOPEPTIDE AND AN IMMUNO: REGULATOR CONTGIT - USED IN THE TREATMENT OF AUTO: IMMUNE DISEASE, 1999	
		LAHTEENOJA et al., LOCAL CHALLENGE ON ORAL MUCOSA WITH AN ALPHA-GLIADIN RELATED SYNTHETIC PEPTIDE IN PATIENTS WITH CELIAC DISEASE, 2000, Am. J. Gastroenterol., 95: 2880	
		SCHUPPAN, CURRENT CONCEPTS OF CELIAC DISEASE PATHOGENESIS, 2000, Gastroenterology, 119, 234-42	
		WIESER, THE PRECIPITATING FACTOR IN COELIAC DISEASE, 1995, Baillieres Clin Gastroenterol, 9(2):191-207	
		WIESER, 1996, RELATION BETWEEN STRUCTURE AND COELIAC TOXICITY, Acta Paediatr Suppl., 412:3-9	
		YOSHIMOTO et al., PROLYL ENDOPEPTIDASE FROM FLAVOBACTERIUM MENINGOSEPTICUM: CLONING AND SEQUENCING OF THE ENZYME GENE, 1991, J. Biochem., 110, 873-8	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.